Atypical Antipsychotics-Induced Glucose and Lipid Metabolism Disorders and Therapeutic Intervention.

Antipsychotics represent the mainstay of pharmacological therapy for schizophrenia and psychiatric disorders with psychotic symptoms. Atypical antipsychotics are the most commonly used in clinics, accompanied by adverse metabolic reactions such as increased body mass, metabolic disorders, dyslipidemia, and poor tolerance to glucose stimulation, which always reduce the life expectancy of psychotic patients. Here, we searched the database for original and review articles in English and elucidated the existing mechanisms involved in the pathogenesis of atypical antipsychotic-induced glucose and lipid metabolism disorders, which occur in the hypothalamus, liver, pancreas β-cells, adipose tissue, and skeletal muscle. Furthermore, we summarized chemical therapeutics such as liraglutide and topiramate, which could be used in combination with atypical antipsychotics against metabolic disorders caused by atypical antipsychotics, providing clues for future research and therapeutic strategy development.